Necessity of add-on therapy in the treatment of hypertension: a new marker of high cardiovascular risk?

Editorial

Josep Redon. J Hypertens. 2012 Nov.

. 2012 Nov;30(11):2085-7.

doi: 10.1097/HJH.0b013e328359b1b8.

No abstract available

Comment on

Higher cardiovascular risk and impaired benefit of antihypertensive treatment in hypertensive patients requiring additional drugs on top of randomized therapy: is adding drugs always beneficial?
Zhang Y, Zhang X, Liu L, Wang Y, Tang X, Zanchetti A; FEVER Study Group. Zhang Y, et al. J Hypertens. 2012 Nov;30(11):2202-12. doi: 10.1097/HJH.0b013e3283582eec. J Hypertens. 2012. PMID: 22990352 Clinical Trial.
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH, Hua TA, McInnes GT, Schork A, Mancia G, Zanchetti A. Weber MA, et al. J Hypertens. 2012 Nov;30(11):2213-22. doi: 10.1097/HJH.0b013e3283582ed6. J Hypertens. 2012. PMID: 23011525 Clinical Trial.